|
|
|
| Clinical Efficacy of Recombinant Human Brain Natriuretic Peptide Combined with Bisoprolol in the Treatment of Patients with Ischemic Cardiomyopathy and its Effect on CITED2, miR-182 and HIF-1 |
| ZHOU Fang-zhou, ZHAO Qing-yan, WANG Ai-hong |
| Shandong Provincial Third Hospital,Jinan Shandong 250031 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of recombinant human brain natriuretic peptide combined with bisoprolol in the treatment of patients with ischemic cardiomyopathy (ICM) and its effect on the levels of microRNA-182 (miR-182), protein trans acting factor (CITED2) and hypoxia inducible factor-1 (HIF-1). 【Methods】A total of 128 ICM patients treated in the Third Hospital of Shandong Province from October 2018 to October 2020 were prospectively selected and divided into observation group and control group according to the random number table method, with 64 cases in each group. On the basis of routine treatment, the control group was treated with bisoprolol, and the observation group was treated with recombinant human brain natriuretic peptide on the basis of the control group. The clinical efficacy and adverse reactions of the two groups were compared, and the levels of serum cardiomyocyte apoptosis index [soluble apoptosis related factor (sFas), soluble apoptosis related factor ligand (sFasL)], markers of myocardial ischemia injury[troponin T (cTnT), myoglobin (Mb), creatine kinase isoenzyme (CK-MB)] and CITED2, miR-182 and HIF-1 were compared before and after treatment.【Results】After one month of treatment, the total effective rate in the observation group was higher than that in the control group (P<0.05); The levels of serum sFas, sFasL, cTnT, Mb and CK-MB in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05); The levels of serum CITED2 in the two groups were higher than those before treatment, and the levels of miR-182 and HIF-1 were lower than those before treatment, and the difference between the two groups was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was higher than that in the control group, but the difference was not statistically significant (P>0.05). 【Conclusion】Recombinant human brain natriuretic peptide combined with bisoprolol is effective in the treatment of ICM patients. It can enhance the ability of myocardial anti hypoxia and ischemia, inhibit cardiomyocyte apoptosis, and has good safety.
|
|
Received: 12 April 2021
|
|
|
|
|
|
[1] 赵霜,刘晓程,刘志刚.缺血性心肌病的外科治疗进展[J].中国心血管病研究,2020,18(4):379-384.
[2] 李兵,苗豫东,刘晓宇,等.肌钙蛋白I自身抗体对缺血性心肌病患者生活质量及预后的影响[J].中华急诊医学杂志,2019,28(2):241-246.
[3] 翟虎,李彤,王禹,等.丹蒌片联合比索洛尔治疗冠心病心绞痛的临床研究[J].现代药物与临床,2019,34(2):341-345.
[4] 闫海艳,程栋,李云鹏,等.心通口服液联合重组人脑利钠肽治疗急性心肌梗死后心力衰竭的临床研究[J].现代药物与临床,2020,35(12):2352-2355.
[5] PENG Y,WEI H.Role of recombinant human brain natriuretic peptide combined with sodium nitroprusside in improving quality of life and cardiac function in patients with acute heart failure[J].Exp Ther Med,2020,20(1):261-268.
[6] 刘倩,龚博君,蒋亚斌,等.重组人脑利钠肽对比常规药物治疗心力衰竭的Meta分析[J].中国老年学杂志,2017,37(14):3455-3457.
[7] 康锐.比索洛尔、美托洛尔治疗左室射血分数保留的心力衰竭的临床对照研究[J].实用药物与临床,2019,22(2):155-158.
[8] LIANG L,TANG R,XIE Q,et al.The clinical effect of recombinant human brain natriuretic peptide on asymptomatic peri-procedural myocardial injury after percutaneous transluminal coronary angioplasty[J].Sci Rep,2020,28(1):15902.
[9] 胡雪梅,张彩云,王敏.CK-MB、CT-1、cTnT在新生儿缺氧损伤心肌细胞中的表达水平及其临床意义[J].中西医结合心脑血管病杂志,2020,18(18):3083-3086.
[10] 董小莉,谭宁,马立宁,等.脑钠肽后处理对大鼠缺血再灌注损伤心肌细胞凋亡的保护作用与机制研究[J].中国循证心血管医学杂志,2020,12(9):1087-1090.
[11] 张莹.尼可地尔对ACS患者PCI术后心肌损伤的防治作用[J].西南国防医药,2019,29(1):24-27.
[12] 李冀,李想,胡晓阳,等.中医药疗法调节miRNA对心肌缺血再灌注损伤影响的研究进展[J].上海中医药杂志,2020,54(3):97-100. |
|
|
|
2022, Vol. 39 
